Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Change in Accured Expenses (2020 - 2021)

Design Therapeutics' Change in Accured Expenses history spans 2 years, with the latest figure at -$26000.0 for Q4 2021.

  • For Q4 2021, Change in Accured Expenses fell 103.6% year-over-year to -$26000.0; the TTM value through Dec 2021 reached $2.4 million, up 69.09%, while the annual FY2025 figure was $4.5 million, 468.01% up from the prior year.
  • Change in Accured Expenses for Q4 2021 was -$26000.0 at Design Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.5 million in Q3 2020 and bottomed at -$1.8 million in Q1 2020.